Search PubMed⌕ Search

Biomedical subjects

G Gunella

Publications and source records attributed to G Gunella.

29 records · Page 2Linked to original sources
PubMedDate not supplied

Pulmonary vascular reactivity and hemorheology in patients with chronic cor pulmonale: responses to pentoxifylline at rest and during exercise.

This study was carried out in order to evaluate changes in pulmonary vascular reactivity and in hemorheology induced by pentoxifylline infusion (100 mg) at rest and during standardized exercise in patients with chronic cor pulmonale secondary to chronic obstructive pulmonary disease. The administration of pentoxifylline at rest was associated with reduction in mean pulmonary artery pressure (p less than 0.01), pulmonary vascular resistance (p less than 0.01) and right ventricular stroke work index (p less than 0.02). Standard exercise performed after pentoxifylline infusion was also associated with significant reduction in mean pulmonary artery pressure and pulmonary vascular resistance. Rheologic tests showed less evident changes. Our data suggest that pentoxifylline significantly improves pulmonary hemodynamics at rest and partly reverses its changes, after exercise, in patients with chronic obstructive pulmonary disease.

Blood Viscosity↗
PubMedDate not supplied

Prevention of non-specific bronchial hyperreactivity. Dose-dependent effect of sodium cromoglycate metered dose aerosol.

The protective effect of different doses of sodium cromoglycate (4 mg, 12 mg and 20 mg) given as pressurized aerosol on fog-induced bronchoconstriction were investigated in three different groups of asthmatic patients. Premedication with the active drug was compared versus absence of premedication. The authors discuss their results by a statistical analysis of the FEV1 variations. Sodium cromoglycate effectively prevents fog-induced bronchoconstriction with a clear dose-dependent effect.

Adolescent↗
PubMedDate not supplied

Efficacy and tolerability of nedocromil sodium versus placebo in chronic reversible obstructive airways disease.

In this 8-week, double-blind, comparative trial of nedocromil sodium (4 mg q.i.d.) versus placebo in 42 patients with chronic reversible obstructive airways disease, there was a trend in favor of nedocromil sodium compared to placebo in parameters assessed by patients (nocturnal symptom scores, evening PEFR values) and those assessed by clinicians (asthma severity scores) compared with baseline values. There was a statistically significant difference (p < 0.05) in favor of nedocromil sodium in the inhaled bronchodilator requirements in the last 2 weeks of treatment. Both patients' and clinicians' evaluation of the overall efficacy of treatment was significant in favor of nedocromil sodium (p < 0.01 and p < 0.05, respectively). The treatments were well tolerated by the majority of patients. From these data, it can be concluded that nedocromil sodium (4 mg q.i.d.) is of value in the preventive treatment of chronic reversible obstructive airways disease.

Adult↗